Molecular Partners (NASDAQ:MOLN - Get Free Report)'s stock had its "sell (d-)" rating restated by research analysts at Weiss Ratings in a research report issued to clients and investors on Tuesday,Weiss Ratings reports.
Separately, JPMorgan Chase & Co. cut their target price on shares of Molecular Partners from $4.50 to $4.00 and set a "neutral" rating on the stock in a research report on Wednesday, September 3rd. One analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock has an average rating of "Hold" and an average price target of $8.00.
Read Our Latest Analysis on Molecular Partners
Molecular Partners Trading Down 6.2%
NASDAQ MOLN traded down $0.24 on Tuesday, hitting $3.56. 3,217 shares of the company were exchanged, compared to its average volume of 5,949. The firm has a 50 day moving average of $3.71 and a two-hundred day moving average of $3.78. The company has a market cap of $143.55 million, a P/E ratio of -1.71 and a beta of 1.09. Molecular Partners has a 1-year low of $3.36 and a 1-year high of $7.60.
Molecular Partners (NASDAQ:MOLN - Get Free Report) last issued its quarterly earnings results on Monday, August 25th. The company reported ($0.67) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.53) by ($0.14). Research analysts anticipate that Molecular Partners will post -1.93 EPS for the current fiscal year.
About Molecular Partners
(
Get Free Report)
Molecular Partners AG, a clinical-stage biotechnology company, develops designed ankyrin repeat proteins therapeutics for the treatment of oncology and virology diseases in Switzerland. The company develops MP0317, a CD40 agonist designed to activate immune cells within the tumor microenvironment by anchoring to fibroblast activation protein that is in Phase I clinical trial; and MP0533, a novel tetra-specific T cell-engaging DARPin for acute myeloid leukemia.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Molecular Partners, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Molecular Partners wasn't on the list.
While Molecular Partners currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
